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Abstract
Gonadal function is critically dependant on regulated secretion of the gonadotropin hormones
from anterior pituitary gonadotroph cells. Gonadotropin biosynthesis and release is triggered by
the binding of hypothalamic GnRH to GnRH receptor expressed on the gonadotroph cell surface.
The repertoire of regulatory molecules involved in this process are still being defined. We used the
mouse LβT2 gonadotroph cell line, which expresses both gonadotropin hormones, as a model to
investigate GnRH regulation of gene expression and differential display reverse transcription-
polymerase chain reaction (RT-PCR) to identify and isolate hormonally induced changes. This
approach identified Fanconi anemia a (Fanca), a gene implicated in DNA damage repair, as a
differentially expressed transcript. Mutations in Fanca account for the majority of cases of Fanconi
anemia (FA), a recessively inherited disease identified by congenital defects, bone marrow failure,
infertility, and cancer susceptibility. We confirmed expression and hormonal regulation of Fanca
mRNA by quantitative RT-PCR, which showed that GnRH induced a rapid, transient increase in
Fanca mRNA. Fanca protein was also acutely upregulated after GnRH treatment of LβT2 cells. In
addition, Fanca gene expression was confined to mature pituitary gonadotrophs and adult mouse
pituitary and was not expressed in the immature αT3-1 gonadotroph cell line. Thus, this study
extends the expression profile of Fanca into a highly specialized endocrine cell and demonstrates
hormonal regulation of expression of the Fanca locus. We suggest that this regulatory mechanism
may have a crucial role in the GnRH-response mechanism of mature gonadotrophs and perhaps
the etiology of FA.
Keywords
anterior pituitary; gene regulation; gonadotropin-releasing hormone; mechanisms of hormone
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INTRODUCTION
Reproduction requires regulated pulsatile release of the gonadotropin hormones, LH and
FSH, from the gonadotroph cells of the anterior pituitary to stimulate gonadal function. The
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gonadotropin hormones are heterodimeric proteins, comprised of a common α subunit
(αGSU) and a hormone-specific β subunit. Their biosynthesis and release is triggered by the
binding of decapeptide GnRH to its cognate receptor (GnRHr), this stimulates second
messenger signaling pathways, which, coupled with GnRHr number and turnover, combine
to differentially regulate hormone biosynthesis [1-3]. Indeed, the pattern of GnRH
administration is crucial for upregulating the mRNA levels of the constituent αGSU and β
subunits that comprise LH and FSH, both in vivo [4, 5] and in vitro [6, 7].
Gonadotroph cell lines recapitulate the embryonic anterior pituitary temporal expression
profile of gonadotropin genes [8-10]. Furthermore, because gonadotroph cells only comprise
10-15% of the cells in the anterior pituitary, cell lines afford greater manipulation of
treatment conditions and provide a source of enriched cell-specific material. In this study,
we used LβT2 cells, an immortalized gonadotroph cell line that is GnRH responsive,
expresses GnRHr and all three gonadotropin subunits [9, 11, 12]. In addition, the second
messenger signaling pathways required to transduce the GnRH signal are starting to be
elucidated in these cells [13-16]. Thus, because LβT2 cells express all the features
associated with mature pituitary gonadotrophs, they are a suitable cell model for
investigating regulation of gene expression by GnRH.
To identify and isolate new and novel mRNAs that are differentially regulated by GnRH in
gonadotrophs, which may be important for gonadotropin hormone biosynthesis, differential
display (DD) reverse transcription-polymerase chain reaction (RT-PCR) [17] was performed
on RNA extracted from untreated and GnRH-treated LβT2 cells. This approach identified
that, among others, expression of Fanconi anemia a (Fanca) mRNA, was altered in response
to GnRH treatment. Fanca is a member of a protein complex required for genome
homeostasis [18, 19] and mutations in Fanca account for >60% of cases of Fanconi anemia
(FA), an autosomal recessive inherited disorder. However, the pleiotropic phenotype of FA
patients indicates that other cellular functions may also depend on the FA complex [20].
Therefore, we decided to investigate the expression profile of Fanca mRNA in detail and
report that GnRH acutely upregulates the expression of both Fanca mRNA and protein. This
suggests that Fanca may have a regulatory role in gonadotroph cells, and this is the first
report of distinct hormonal regulation of this gene.
MATERIALS AND METHODS
Cell Culture
LβT2 and αT3-1 cells (obtained from P. Mellon, San Diego, CA) were cultured in DMEM
(Sigma, Dorset, UK) supplemented with 10% FCS (Sigma) and 1% penicillin/streptomycin
(Sigma). All gonadotroph cell culture plasticware was coated with a 1:30 dilution of
Matrigel (Becton Dickinson Labware, Oxford, UK) in PBS (Sigma). Cells were treated with
1 μM of native GnRH (Peninsula, St. Helens, UK) for 15 min. This concentration is known
to stimulate high levels of LH and FSH β subunit gene expression [21, 22], with an
interpulse interval of 75 min, for either 3 or 6 pulses; fresh media was added and the cells
harvested or cells were treated with one 15-min pulse and harvested 1, 2, or 4 h post-GnRH
treatment into RNAzol B (AMS Biotechnology, Abingdon, UK) and stored at −70°C.
Mouse L-cells and HeLa cells (ECACC, CAMR, Porton Down, UK) were passaged in
growth media as described above, and all cells were grown in a humidified 5% CO2
atmosphere at 37°C.
Differential Display RT-PCR
RNA was extracted as per the manufacturer’s protocol and differential display was
performed as described [17], with further modifications [23]. Briefly, cDNA was generated
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using a First Strand cDNA synthesis kit (Amersham Pharmacia Biotech, Little Chalfont,
UK) and degenerate oligo(dT) primers (primers have 12 thymidine bases and a combination
of two random bases TTTTTTTTTTTTVN where V and N = A, G, or C). The oligo(dT)
primers were pooled into 3 × 24 μM mixes; T12VA, T12VC, and T12VG were used to prime
first-strand cDNA subpopulations. DD-RT-PCR was performed using oligo(dT) and random
10-mer primers (Sigma-Genosys, Pampisford, UK), which are listed in Table 1. The 20-μl
reaction mix contained 5 μl of cDNA (pipetted from a 1:131-μl dilution of the first-strand
reaction), 0.5 μM random primer, 3 mM MgCl2, 2.4 μM T12VC, 2 μM dNTP’s (Amersham
Pharmacia Biotech), 1 μl 35S-dATP (1000 Ci/mmol, Amersham Pharmacia Biotech), 0.3 μl
AGS Gold Taq polymerase, 2 μl each reaction buffer and enhancer (Hybaid, Ashford, UK),
and 1.2 μl H2O. The PCR reaction conditions were as described [23]. A 4-μl aliquot was
loaded on a 6% acrylamide gel (HR-1000; Beckman Coulter UK Ltd, High Wycombe, UK)
and electrophoresed on a GenomyxLR DNA analyzer (Beckman Coulter) at 2700 V for 2 h
15 min at 50°C. The gel was transferred to 3MM paper (Whatman, Fisher Scientific,
Loughborough, UK) dried, and bands were visualized using BiomaxMR autoradiographic
film (Amersham Pharmacia Biotech), excised and rehydrated in 150 μl low TE (10 mM Tris
HCI, 0.1 mM EDTA, pH 7.4). The DNA was eluted at 100°C, ethanol precipitated, and
resuspended in 10 μl of low TE. To facilitate subcloning, this was combined with a 40-μl
reaction mix (3 mM MgCl2, 0.3 μl AGS Gold, 4 μl buffer, 4 μl Enhancer, 0.8 mM dNTP,
1.25 μM T12VN, 1.25 μM random primer, and 11 μl H2O) and amplified by PCR before
splitting into four 10-μl aliquots and reamplified. The Fanca fragment was cloned into pT7-
Blue (Novagen, CN Biosciences Ltd., Beeston, UK) using the Perfectly Blunt cloning kit
(Novagen) and sequenced.
Northern blotting, Semiquantitative and Quantitative RT-PCR
Total RNA (40 μg) was fractionated, Northern blotted, and probed, then quantified as
described [24]. Radiolabeled probes used corresponded to either the 5′ region (exons 1-11)
or the 3′ region (exons 42-43) of Fanca cDNA.
RT-PCR was performed by reverse transcribing 1 μg RNA using First Strand cDNA
synthesis kit (Amersham Pharmacia Biotech) and 1 μl was added to a 25-μl reaction
containing 2 μM upstream and downstream primers and 10 μl Extensor High Fidelity
Master Mix Buffer 2 (AB Gene, Epsom, UK). Standard PCR conditions were used and were
identical for Fanca and penta zinc-finger protein 276 (Zfp276). For details of primers and
PCR fragments, see Table 2. PCR products were verified by sequencing individual clones
after ligation into TA-cloning vectors (Invitrogen, UK) using ABI big dye terminator
reagents (ABI, Warrington, UK). DNA fragments were visualized on an ethidium bromide-
stained agarose gel, which for Fanca was Southern blotted and probed with a radiolabeled
probe (exons 7-17) before exposing to x-ray film.
Quantitative RT-PCR was performed for Fanca mRNA using a LightCycler Instrument
(Roche Diagnostics, Lewes, East Sussex, UK), FastStart DNA Master SYBR Green I
(Roche Diagnostics), and mouse beta-2-microglobulin (B2m) as an internal control. Specific
primers are shown in Table 2. Each LightCycler reaction consisted of 5.8 μl dH2O, 1.2 μl
MgCl2 (4 mM), 1 μl Primer Pair Mix (25 μM each), 1 μl LightCycler DNA Master SYBR
Green I (Roche Diagnostics), and 1 μl cDNA. The LightCycler program used for Fanca and
B2m real-time PCR was as follows: one cycle of 95°C for 10 min, 60 cycles of 95°C for 5
sec, 57°C for 5 sec, and 72°C for 15 sec, and a melting curve program (57-95°C). A
standard curve of Fanca and B2m expression was determined using serially diluted cDNA
made from mouse L-cell RNA. Results are expressed as arbitrary units of Fanca mRNA
expression normalized against B2m mRNA expression levels and are a mean of three
separate experiments performed in duplicate.
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Western Blotting Analysis
LβT2 cells were left untreated or were treated with GnRH and harvested 2, 4, or 6 h later.
Whole-cell extracts were prepared by washing the cell monolayer in ice-cold PBS with
Complete (Roche Diagnostics) protease inhibitors, before scraping into a 1.5-ml centrifuge
tube, which was frozen on dry ice. Total cellular protein was liberated by three rapid freeze-
thaw cycles, and cellular debris was cleared by centrifugation at 4°C for 5 min at 20 000 × g.
Protein concentration was determined using Bio-Rad protein assay reagent (Bio-Rad, Hemel
Hempstead, UK), 50 μg of whole-cell extract was boiled in 1× loading buffer (62.5 mM
Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 0.01% Bromophenol Blue, 1% β-
mercaptoethanol), fractionated on a 6% SDS-PAGE gel, and electroblotted overnight at 25
V onto Immobilon-P (Millipore, Watford, UK) in 1× TGS/20% methanol (TGS; 25 mM
Tris, pH 8.8, 250 mM glycine, 0.1% SDS). Blots were probed as described [5] with anti-
mouse Fanca antisera raised to amino acids 1-271 (kind gift from Dr. Fre Arwert, VU
University Medical Center, Amsterdam, The Netherlands) at a concentration of 1:1500, then
stripped in 2% SDS, 50 mM Tris, pH 6.8, 0.7% β-mercaptoethanol at 55°C for 30 min
before washing and reprobing with anti-mouse β-tubulin antisera at a concentration of 1:500
(Santa Cruz Biotechnology Inc., Santa Cruz, CA).
Bioinformatics and Statistics
All bioinformatic comparisons were made using Wisconsin Package Version 10.3 (Accelrys
Inc., San Diego, CA) housed on the Medical Research Council’s Human Genome Mapping
Project server (MRC, HGMP, Hinxton, UK). Statistical differences were determined using
one-way analysis of variance (ANOVA), with P < 0.05 deemed significant.
RESULTS
Differential Display RT-PCR Analysis of GnRH-Treated LβT2 Cells
LβT2 cells were grown in vitro on Matrigel basement membrane, which contains collagen,
other extracellular basement membrane proteins, growth factors, metalloproteinases, and
factors that promote cell adherence. These factors may upregulate gene expression
independent of GnRH, so to test this, two different treatment regimes were designed. In
regime 1, cells were grown on uncoated or Matrigel-coated flasks, while for regime 2, cells
were grown on Matrigel and left untreated or treated with GnRH. RNA was isolated and
subjected to DD-RT-PCR analysis (Fig. 1A). There was no visible alteration in DD-RT-PCR
generated transcripts between cells grown on uncoated or Matrigel-coated flasks, while
addition of GnRH clearly affected transcript levels. This treatment regime has previously
been used to regulate expression and trigger pulsatile release of LH from these cells [9].
However, we found that a short 15-min pulse of GnRH induced rapid changes in gene
expression (Fig. 1B). The identified 216-base pair (bp) cDNA was isolated, subjected to a
further two rounds of PCR amplification, cloned, and sequenced. Bioinformatic analysis of
the 74-bp DNA sequence obtained produced an identical match to exon 43 of Fanca. The
difference in size between the identified 216-bp DD-RT-PCR product and the amplified 74-
bp cDNA clone was due to internal priming during the second round of PCR amplification,
and the two sets of priming sites are shown in Figure 1C. This was a common feature
(unpublished observation) due to the inherent redundancy of the PCR amplification and may
reflect the poor processivity of some Taq polymerases and preferential cloning of small
DNA fragments. The 216-bp DD-RT-PCR product visible on the gel was consistent with
priming of Fanca mRNA by a T12VC-anchored primer (Fig. 1C). Bioinformatics also
highlighted that the 74-bp cDNA clone obtained could possibly correspond to pentazinc
finger protein 276 (Zfp276) because Zfp276 mRNA is encoded on the opposite DNA strand
from Fanca and overlaps the Fanca gene locus at the 3′ end [25]. The orientation of these
genes and region of DNA overlap between them is indicated in Figure 2. We concluded that
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Zfp276 was unlikely to be the original DD-RT-PCR clone because the mRNA polyA+
addition site and likely T12VC priming site maps a considerable distance downstream and
there was no suitable T12VC annealing site within 200 bp of immediate flanking DNA
sequence. However, because two transcripts, Fanca and Zfp276, matched the cloned DD-
RT-PCR DNA fragment, additional expression analysis was needed to confirm that Fanca
was differentially expressed.
Fanca mRNA Is Differentially Expressed in LβT2 Cells
Northern blotting of total RNA extracted from GnRH-treated LβT2 cells and probing with
5′ and 3′ fragments of mouse Fanca cDNA (Fig. 3A), confirmed that a full-length 4.5-
kilobase (kb) transcript was expressed. The 5′ Fanca probe corresponded to 1-965 bp of the
cDNA, which encodes exons 1-11. The 3′ Fanca probe corresponded to 4231-4500 bp of the
mouse cDNA that encodes exons 42-43 and should cross-hybridize with the Zfp276
transcript that overlaps this coding region. Indeed, a large 4.5-kb Fanca transcript and a
small 3.1-kb transcript corresponding to the reported size of Zfp276 mRNA [25] were
detected. The Northern blot was stripped and reprobed with a ribosomal probe specific for
18s, which was used to control for loading (Fig. 3A).
Although nonquantitative, there appeared to be no difference in expression levels of Zfp276
mRNA amplified by RT-PCR in untreated and treated cells (Fig. 3B). Interestingly,
semiquantitative RT-PCR amplification of Fanca mRNA suggested that Fanca expression
increased 1 h after GnRH treatment. Specific amplification of a 979-bp Fanca PCR product
was confirmed by subsequent Southern blotting analysis, which also identified lower levels
of expression in untreated, and a rapid reduction 2 and 4 h after hormone treatment (Fig.
3C).
Thus, quantitative RT-PCR was used to measure the rapid increase in Fanca mRNA after
GnRH treatment. In this assay, Fanca mRNA clearly increased 2-fold 1 h after GnRH
treatment (P < 0.05) and returned to unstimulated levels by 4 h (Fig. 3D). Taken together,
these results indicate that Fanca, but not Zfp276, mRNA is acutely regulated by GnRH in
LβT2 cells.
Analysis of Fanca Protein Expression
The rapid upregulation of Fanca mRNA may not be mirrored by an increase in protein, so
Western blotting analysis was used to quantify Fanca protein levels in LβT2 cell protein
extracts. First, protein extracts were made from untreated cells and from cells harvested 2 h
after addition of GnRH, and were fractionated on a 6% SDS-PAGE gel, blotted onto
polyvinylidene fluoride (PVDF) and incubated with Fanca antisera specific for amino acids
1-271 [26]. A specific 160-kDa band, corresponding to the expected size of Fanca protein,
was detected in untreated and GnRH-treated extracts (Fig. 4A). Thus, the increase in levels
of Fanca protein was measured over a longer time period following GnRH treatment and
quantified (Fig. 4B). Again, Fanca protein levels increased 2-fold after addition of GnRH for
2 h (P < 0.001). This 2-fold increase was still evident 4 h after treatment with GnRH (P <
0.001), but by 6 h, Fanca protein levels had begun to fall (P < 0.05). This shows that a rapid
increase in Fanca mRNA (Fig. 3D) is followed by a 2-4-h sustained increase in Fanca
protein.
In Vivo and Temporal Expression Profile of Fanca mRNA
We next determined if Fanca was expressed in the pituitary in vivo. Mouse pituitary RNA
was extracted, reverse transcribed, and cDNA amplified using specific primers to Fanca.
DNA bands corresponding to exons 7-18, 14-18, and 30-32 were identified (Fig. 5A). This
analysis confirmed pituitary expression of Fanca in adult mice. Because LβT2 cells are
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derived from embryonic Day 16.5 mouse pituitaries, we also investigated if Fanca mRNA
was expressed in a different immature gonadotroph cell line (Fig. 5B). As expected, Fanca
was expressed in LβT2 cells, HeLa, and L cells, but no corresponding PCR product was
detected in immature precursor αT3-1 gonadotroph cells.
DISCUSSION
Murine Fanca mRNA has a predicted size of 4503 bp, which encodes a 160-kDa protein [27,
28]. Fanca mRNA is relatively highly expressed in lymphoid tissues, testes, and ovary in
adult mice and is activated as early as Embryonic Day 7, largely in cells of epithelial origin
[27, 28]. This is the first report of hormonal regulation of Fanca and of Fanca expression in a
specialized endocrine cell. Although there have been reports of smaller Fanca mRNA
molecules being expressed in brain [27], none of these were localized to the pituitary, and
they may correspond to the recently identified Zfp276 gene [25], because in our hands,
neither Northern nor RT-PCR analysis indicated any variation in size of Fanca mRNA in
LβT2 cells.
Because DD-RT-PCR amplifies the transcriptome, low-abundance messages are represented
with no preselection bias from the user [17, 29]. This approach was particularly suited
toward identification and isolation of Fanca cDNA. Differential GnRH regulation of Fanca
mRNA was confirmed by a combination of semiquantitative and quantitative RT-PCR.
However, the DD-RT-PCR technique does generate high numbers of false positives, and a
number of strategies have been suggested to eliminate this [23, 30, 31]. These were taken
into account during the design of our experiments and briefly include use of a time course,
so differences were easily recognized, RNA extraction and cDNA synthesis was done
simultaneously, and samples from different experiments were electrophoresed in duplicate
to ensure repeatability. Thus, we established that, although Fanca mRNA was expressed at
very low levels in the LβT2 cell line, GnRH regulation was still rapid and transient, with
mRNA returning to unstimulated levels after 2 h. In contrast, when using microarray
analysis, the design of the cDNA microarray determines which transcripts are identified.
Although Fanca was omitted from the microarray, rapid transient increases in transcripts
were measured in response to GnRH treatment, most corresponded to immediate early gene
products that had returned to baseline levels by 3 h post-GnRH treatment, and early growth
factor-1 (Egr-1) and c-Jun were induced over a wide range of GnRH concentrations (1 nM
up to 1 μM) [32, 33]. Because we and others all measure significant increases in gene
expression in LβT2 cells after one treatment with a pharmacological dose of GnRH, this
indicates that, although the concentration of GnRH is important, the timing between GnRH
pulses is also a critical factor. It is not clear if the same changes in gene expression would be
induced with a pulsatile GnRH treatment regime as in the normal physiological state,
although our original experiment did address this by using 15-min pulses separated by an
interpulse interval of 75 min (Fig. 1A), we found it was not ideally suited to isolation of
differentially expressed transcripts and that a shorter time course of induction of gene
expression was preferable.
The rapid, transient increase in Fanca mRNA levels measured in response to GnRH was
followed by a similar, but longer, increase in Fanca protein levels. This suggests that levels
of Fanca mRNA are tightly controlled, and we hypothesize that hormone treatment either
increases Fanca gene transcription and/or stabilizes Fanca mRNA. Measuring steady-state
mRNA levels by quantitative RT-PCR does not distinguish between these two possibilities.
Our observation that Fanca mRNA is highly regulated in a mature GnRH-responsive
gonadotroph cell line, an endocrine tissue, may explain why researchers had difficulties in
detecting Fanca gene expression by in situ hybridization in embryonic mouse testes, but did
detect expression in adult testes [27, 28, 34]. In keeping with the rapid, short-lived peak in
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Fanca mRNA, we consistently found that hormonal stimulation also increased levels of
Fanca protein. Fanca protein increased 2 h after treatment with GnRH, but persisted for
longer, only starting to decline 6 h after treatment. Because we used whole-cell extracts in
this study, we have yet to analyze if this increase in protein also results in a
recompartmentalization of Fanca within the cell in response to hormone, but prior treatment
of cells with cycloheximide, an inhibitor of translation, blocks the GnRH-induced increase
in Fanca protein levels (unpublished results), suggesting that the increase in Fanca protein is
indeed due to de novo translation. The hormonally induced increase in Fanca protein
suggests it may be a component of a rapid response mechanism in these cells. Indeed, the
action of Fanca in immune cells is upstream of the immediate early response genes [35],
suggesting that Fanca may act as part of a signal-transduction cascade. We and others have
noted that expression of Fanca protein is low because detection requires either reasonable
amounts of starting material [27] or an enriched population of cells, indicating that relatively
small changes in protein expression could have a large impact. Interestingly, expression
levels and posttranslational modification are critically important for many proteins involved
in signal transduction [36].
The hormonal regulation of expression and temporal pattern of Fanca gene activation
indicates that this molecule may be important for mature gonadotroph cell function. While
the existence of a complementary Zfp276 transcript complicated our analysis, especially
because it was coexpressed in LβT2 cells, there was no clear evidence to indicate that
Zfp276 mRNA was the original DD-RT-PCR fragment or that it was hormonally regulated.
Furthermore, although Zfp276 mRNA was expressed, neither Fanca mRNA or protein (data
not shown) was detected in αT3-1 cells, which are a GnRH-responsive gonadotroph cell line
derived from embryonic Day 13.5 pituitaries, that exclusively express αGSU, but not LH or
FSH β subunit [10, 37]. This indicates that Fanca gene expression is activated late in
pituitary development because LβT2 cells are derived from embryonic Day 16.5 pituitaries,
and indeed, we confirmed that Fanca was expressed in adult pituitary.
The pleiotropic nature of the FA syndrome, which in humans is an autosomal recessive
disorder characterized by bone marrow failure, aplastic anemia, and variable predisposition
to cancers of the gynecologic system among other clinical features, including infertility [18,
38, 39], has made it difficult to ascribe particular phenotypic features to mutations in any
particular region of Fanca or any of the other Fanconi complementation groups [40, 41].
Targeted disruption of Fanca in mice has reproduced some of the associated FA phenotypes
described above, but the most consistent of these appears to be a severe reduction in fertility
[34, 42, 43]. Furthermore, although the pituitary was not examined, the testes were
identified as a major site of Fanca gene expression, and these mice developed ovarian
granulosa cell tumors [34], a phenotype also known to be consistent with elevated plasma
levels of pituitary LH [44]. Elevated gonadotropin levels have also been reported in FA
patients [45], and there is evidence that FA impacts on reproduction [46, 47]. Taken
together, these observations suggest a role for Fanca in reproduction, especially gonadal
function, but how this impacts on the pituitary is under further investigation.
There may be a link between FA and development of pituitary neoplasms because pituitary
tumors develop through various mechanisms [48]. FA is a relatively rare disease, while the
incidence of pituitary adenoma within the general population is high (∼20%), and
gonadotroph cell neoplasms account for ∼35% of these [49]. However, a specific subset of
pituitary tumors (<2%) are caused by mutations in the MEN1 gene, which encodes the
transcriptional repressor MENIN [50] and interestingly, MENIN has recently been shown to
interact with FANCD2, the downstream target of the FA complex [51].
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In addition, a number of FA genes have been implicated in ovarian tumorigenesis in man
and mouse [52, 53] and Fanca is required for gonadal function [34]. GnRH, acting through
its receptor, is a key autocrine/paracrine regulator of ovarian and testicular function [54] and
has a role in development of GnRH-responsive ovarian, breast, and prostate cancer [55].
This evidence and the prevalence of endocrinopathies in patients support a role for the FA
genes in endocrine signaling [20]. Thus, we hypothesize that GnRH regulation of Fanca
gene expression may be important for the normal endocrine function of the pituitary and
possibly reproductive organs.
In conclusion, Fanca was identified in and isolated from mouse anterior pituitary
gonadotrophs in a DD-RT-PCR screen for transcripts regulated by GnRH. This broadens the
expression profile of Fanca into highly specialized endocrine tissues and establishes
hormonal regulation of the Fanca locus. The acute hormonal regulation of the molecule
indicates that Fanca may have a role in mediating GnRH responsiveness in mature
gonadotrophs.
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FIG. 1.
Differential display RT-PCR analysis of GnRH-regulated transcripts isolated from LβT2
cells. A) Matrigel basement membrane was excluded as an inducer of gene expression in
LβT2 gonadotroph cells while GnRH was shown to upregulate transcripts. Cells were grown
without Matrigel (1) or were cultured on Matrigel (2, 3, and 4) and treated with 3 (3) or 6 (4)
15-min pulses of GnRH with an interpulse interval of 75 min. RNA was extracted and
subjected to differential display (DD) RT-PCR using primers stated. Matrigel did not alter
transcript expression (arrows a and b), while numerous transcripts altered after GnRH
treatment (arrows c and d). B) In two separate experiments, LβT2 cells were left untreated
(−G) or were treated with 1 × 15-min pulse of GnRH (+G), RNA was harvested (−G, 1, 2,
and 4 h) and subjected to DD-RT-PCR. First-strand cDNA was generated using the T12VC
downstream primer, then amplified by PCR using primers R21, MAX1, or R5. Arrow
denotes location of Fanca. The location of DNA size markers, indicated as bp, are also
shown. C) Bioinformatic line-up depicting the region of homology, shown underlined,
between the cloned Fanca DD-RT-PCR product and mouse Fanca cDNA nucleotide
sequence, and the likely internal R5 priming site. The location of DD-RT-PCR primers R5
and T12VC that generated the original 216-bp DD-RT-PCR product are also indicated.
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FIG. 2.
Schematic representation of the Fanca locus showing the location of the differential display
RT-PCR clone. Exons 40-43 of Fanca, shown as black boxes, overlap with the 3′
untranslated region (UTR) of Zfp276, shown in grey. The location of the cloned 74-bp
differential display (DD) RT-PCR clone is indicated. Beneath the schematic, the regions of
nucleotide identity between Fanca mRNA and Zfp276 mRNA have been aligned, Fanca
mRNA sequence is shown in bold type, and spliced intronic sequence has been omitted and
replaced with a dashed line, with Zfp276 mRNA in normal typeface. The amplified 74-bp
DD-RT-PCR clone has been boxed with a solid line, and the original 216-bp DD-RT-PCR
clone is indicated as an extension of the boxed region with dashed lines. The amplification
primers R5 and T12VC are also shown on the corresponding Fanca sequence. No suitable
priming sites were identified by bioinformatic analysis for the T12VC-anchored primer on
the Zfp276 3′ UTR sequence.
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FIG. 3.
Characterization and quantification of Fanca and Zfp276 mRNA after GnRH treatment. A)
Confirmation of expression of full-length 4.5-kb Fanca and 3.1-kb Zfp276 mRNA
transcripts in LβT2 cells. Total RNA from LβT2 cells was fractionated on a formaldehyde
gel, Northern blotted, and probed with radiolabeled probes corresponding to either the 5′
region (exons 1-11) or 3′ region (exons 42-43) of Fanca. The blot was then stripped and
reprobed with an 18s probe. Specific Fanca, Zfp276, and 18s bands are indicated by arrows.
B) Semiquantitative RT-PCR analysis of Zfp276 expression. LβT2 cells were left untreated
(0) or treated with 1 × 15-min pulse of GnRH, then harvested 1, 2, and 4 h later, RNA was
extracted, and first-strand cDNA made. PCR was performed to amplify full-length Zfp276
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(1238 bp) and the products were visualized on an ethidium bromide-stained agarose gel.
One specific 1238-bp PCR product was visible at all time points. L-cell cDNA was included
as a positive control. An arrow denotes the 1238-bp PCR product, and DNA size markers
are labeled. C) Semiquantitative RT-PCR analysis was performed for Fanca expression in
LβT2 cells that were left untreated (0) or treated with 1 pulse of GnRH; harvested 1, 2, and
4 h later; RNA extracted, and cDNA made. Ethidium bromide staining identified one PCR
product amplified from mRNA harvested from the 1-h time point. L-cell cDNA was
included as a positive control. An arrow denotes the 979-bp PCR product, and size markers
are labeled. Southern blotting analysis of the agarose gel with a 5′ Fanca probe confirmed
that the Fanca PCR product was specific and present at all time points. D) LightCycler
quantitative RT-PCR analysis of Fanca mRNA extracted from LβT2 cells either left
untreated or treated with GnRH and harvested 1, 2, and 4 h later detected a consistent 2-fold
increase in Fanca mRNA harvested 1 h after treatment. Results are shown as arbitrary units
(AU) of Fanca mRNA normalized against the levels of internal control B-2-microglobulin
(B2m) mRNA. This experiment was performed in duplicate and repeated three times. *P <
0.05 was determined as being significant by ANOVA one-way analysis of variance.
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FIG. 4.
Western blotting analysis of Fanca protein. A) Western blotting analysis of protein extracts
from untreated, 0, and extracts harvested 2 h after GnRH treatment identified Fanca protein.
Cellular protein was fractionated, transferred to PVDF, and probed with anti-mouse Fanca
antisera before being stripped and reprobed with anti-mouse β-tubulin. Arrows indicate the
160-kDa Fanca and 55-kDa β-tubulin proteins. B) Western blotting analysis of whole-cell
protein extracts from untreated (0) and hormone-treated cells harvested 2, 4, and 6 h later.
Blots were probed as above in A. ANOVA one-way analysis of variance determined that the
increases in Fanca protein levels after hormone treatment were significant: ***P < 0.001;
***P < 0.001; *P < 0.05.
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FIG. 5.
Fanca is expressed in adult mouse pituitary. A) RT-PCR analysis of RNA extracted from
adult mouse pituitary was performed using primers that amplified exons 7-18, exons 14-18,
and exons 30-32 of mouse Fanca. Ethidium bromide staining identified PCR products for all
regions amplified. A control GAPDH PCR product was also amplified, confirming the
integrity of the mouse pituitary cDNA. B) RNA was extracted from LβT2, αT3-1, HeLa,
and L cells; reverse transcribed; and first-strand cDNA was analyzed by PCR for expression
of Fanca. The PCR primers corresponded to exons 7-18 of mouse Fanca cDNA and
ethidium bromide staining identified a 450-bp product in LβT2, HeLa, and L cells. No
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Fanca expression was detectable when amplifying αT3-1 cDNA. In this experiment,
expression of Zfp276 was used as an internal control to check PCR conditions and RNA
integrity. A specific 1238-bp PCR product, corresponding to Zfp276, was amplified from
LβT2, αT3-1, and L cell first-strand cDNA.
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TABLE 1
Differential display (DD) RT-PCR random 10-mer primers.
DD-RT-PCR random 10-mer primer DNA sequence
TK 5′-CTTGATTGCC-3′
A1 5′-ACAGAGCACA-3′
A2 5′-ACGTATCCAG-3′
MAX1 5′-GAGCATATCC-3′
MAX2 5′-CACAGCTTGC-3′
MAX3 5′-CCACAGAGTA-3′
R21 5′-AGTCAGCCAC-3′
R5 5′-AGGACCCTGG-3′
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TABLE 2
Specific primers were used in PCR reactions to amplify first strand Fanca, Zfp276, and B-2-microglobulin
cDNA.
Specific primers* DNA sequence Location PCR product (base pairs)
Fanca s 5′-CTGTGTGAGCAGATAGGC-3′ Exon 7 (640 bp) 979
Fanca as 5′-TCACGCTCGGCAATGTCCC-3′ Exon 17 (1619 bp)
Fanca s 5′-CAGCATGGTCACTGCGTTCC-3′ Exon 14 (1263 bp) 450
Fanca as 5′-CCTGAATATGCTGGCCTCCA-3′ Exon 18 (1713 bp)
Fanca s 5′-GTGGTGGAGACCTGGAAGA-3′ Exon 30 (2900 bp) 211
Fanca as 5′-CGGCGTAGAACAGCCATG-3′ Exon 32 (3111 bp)
Fanca s 5′-GCACTTTGCGTGGAGAGG-3′ Exon 37 (3666 bp) 129
Fanca as 5′-CAGGTAGGACGAGAGTAGAC-3′ Exon 38 (3795 bp)
Zfp276 s 5′-CACTGTCCTCTGAGTACTGC-3′ 5′ ATG 68 bp 1238
Zfp276 as 5′-CGTCACCTGCTGAGTTCAAG-3′ 3′ ATG 1170 bp
B2m s 5′-ATGGCTCGCTCGGTGACCCTGGT-3′ Exon 1 (ATG) 102
B2m as 5′-TGTTCGGCTTCCCATTCTCC-3′ Exon 1 (102 bp)
*
Primer annealing sites are expressed relative to the translational start site (ATG) in Fanca, Zfp276, and B-2-microglobulin (B2m). s, Sense; as,
antisense; bp, base pairs.
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